Cargando…
Neutralizing antibody titres in SARS-CoV-2 infections
The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782739/ https://www.ncbi.nlm.nih.gov/pubmed/33397909 http://dx.doi.org/10.1038/s41467-020-20247-4 |
_version_ | 1783631966640275456 |
---|---|
author | Lau, Eric H. Y. Tsang, Owen T. Y. Hui, David S. C. Kwan, Mike Y. W. Chan, Wai-hung Chiu, Susan S. Ko, Ronald L. W. Chan, Kin H. Cheng, Samuel M. S. Perera, Ranawaka A. P. M. Cowling, Benjamin J. Poon, Leo L. M. Peiris, Malik |
author_facet | Lau, Eric H. Y. Tsang, Owen T. Y. Hui, David S. C. Kwan, Mike Y. W. Chan, Wai-hung Chiu, Susan S. Ko, Ronald L. W. Chan, Kin H. Cheng, Samuel M. S. Perera, Ranawaka A. P. M. Cowling, Benjamin J. Poon, Leo L. M. Peiris, Malik |
author_sort | Lau, Eric H. Y. |
collection | PubMed |
description | The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT(90)) and 50% (PRNT(50)) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT(50) titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT(50) antibody titres to decrease by half (T(1/2)) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT(90) and PRNT(50) antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals. |
format | Online Article Text |
id | pubmed-7782739 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-77827392021-01-11 Neutralizing antibody titres in SARS-CoV-2 infections Lau, Eric H. Y. Tsang, Owen T. Y. Hui, David S. C. Kwan, Mike Y. W. Chan, Wai-hung Chiu, Susan S. Ko, Ronald L. W. Chan, Kin H. Cheng, Samuel M. S. Perera, Ranawaka A. P. M. Cowling, Benjamin J. Poon, Leo L. M. Peiris, Malik Nat Commun Article The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century. Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing antibody responses are needed. We tested 293 sera from an observational cohort of 195 reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infections collected from 0 to 209 days after onset of symptoms. Of 115 sera collected ≥61 days after onset of illness tested using plaque reduction neutralization (PRNT) assays, 99.1% remained seropositive for both 90% (PRNT(90)) and 50% (PRNT(50)) neutralization endpoints. We estimate that it takes at least 372, 416 and 133 days for PRNT(50) titres to drop to the detection limit of a titre of 1:10 for severe, mild and asymptomatic patients, respectively. At day 90 after onset of symptoms (or initial RT-PCR detection in asymptomatic infections), it took 69, 87 and 31 days for PRNT(50) antibody titres to decrease by half (T(1/2)) in severe, mild and asymptomatic infections, respectively. Patients with severe disease had higher peak PRNT(90) and PRNT(50) antibody titres than patients with mild or asymptomatic infections. Age did not appear to compromise antibody responses, even after accounting for severity. We conclude that SARS-CoV-2 infection elicits robust neutralizing antibody titres in most individuals. Nature Publishing Group UK 2021-01-04 /pmc/articles/PMC7782739/ /pubmed/33397909 http://dx.doi.org/10.1038/s41467-020-20247-4 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Lau, Eric H. Y. Tsang, Owen T. Y. Hui, David S. C. Kwan, Mike Y. W. Chan, Wai-hung Chiu, Susan S. Ko, Ronald L. W. Chan, Kin H. Cheng, Samuel M. S. Perera, Ranawaka A. P. M. Cowling, Benjamin J. Poon, Leo L. M. Peiris, Malik Neutralizing antibody titres in SARS-CoV-2 infections |
title | Neutralizing antibody titres in SARS-CoV-2 infections |
title_full | Neutralizing antibody titres in SARS-CoV-2 infections |
title_fullStr | Neutralizing antibody titres in SARS-CoV-2 infections |
title_full_unstemmed | Neutralizing antibody titres in SARS-CoV-2 infections |
title_short | Neutralizing antibody titres in SARS-CoV-2 infections |
title_sort | neutralizing antibody titres in sars-cov-2 infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782739/ https://www.ncbi.nlm.nih.gov/pubmed/33397909 http://dx.doi.org/10.1038/s41467-020-20247-4 |
work_keys_str_mv | AT lauerichy neutralizingantibodytitresinsarscov2infections AT tsangowenty neutralizingantibodytitresinsarscov2infections AT huidavidsc neutralizingantibodytitresinsarscov2infections AT kwanmikeyw neutralizingantibodytitresinsarscov2infections AT chanwaihung neutralizingantibodytitresinsarscov2infections AT chiususans neutralizingantibodytitresinsarscov2infections AT koronaldlw neutralizingantibodytitresinsarscov2infections AT chankinh neutralizingantibodytitresinsarscov2infections AT chengsamuelms neutralizingantibodytitresinsarscov2infections AT pereraranawakaapm neutralizingantibodytitresinsarscov2infections AT cowlingbenjaminj neutralizingantibodytitresinsarscov2infections AT poonleolm neutralizingantibodytitresinsarscov2infections AT peirismalik neutralizingantibodytitresinsarscov2infections |